期刊
CLINICAL GENITOURINARY CANCER
卷 14, 期 6, 页码 465-472出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clgc.2016.04.001
关键词
Advanced renal cell carcinoma; Cytoreductive nephrectomy; Meta-analysis; Molecular agents; Overall survival
Cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) (resection of the primary tumor for debulking purposes) was considered to be an important part of oncological treatment when used with cytokines, and was associated with an overall survival (OS) benefit. However, the role of CN in the targeted therapy era is not well-defined. We conducted a systematic review and meta-analysis to determine the prognostic role of CN performed during the course of advanced disease in patients with mRCC treated with molecular agents. We searched PubMed, EMBASE, the Web of Science, Google Scholar, CINAHL, LILACS, the Cochrane Library, and SCOPUS for studies reporting survival data for participants who underwent CN with targeted therapy (CN+) versus those treated with targeted therapy alone (CN). In a multivariate analysis, data were aggregated using hazard ratios with 95% confidence intervals for OS related to CN+. Twelve studies involving 39,953 patients were identified. In 11 publications with OS data available, the patients treated with CN+ had a reduced risk of death compared with those treated with targeted therapies alone (hazard ratio, 0.46; 95% confidence interval, 0.32-0.64; P < .01; l(2) = 99%). Based on these results, CN+ reduces the risk of death in mRCC by more than 50% and should be discussed and included in the therapeutic armamentarium, as it still plays a therapeutic role, even in the post-cytokine era. (C) 2016 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据